Completion of the phase 2 clinical trial evaluating DAV132 in patients
Success of the phase 2 clinical trial (SHIELD) evaluating DAV132 in patients.
The SHIELD trial showed that DAV132 was safe for use in hospitalized elderly patients with several comorbidities and taking concomitant medications. It also demonstrated that DAV132 was able to protect the intestinal microbiome from antibiotic damage.
It is the first phase 2 clinical trial assessing DAV132 safety and ability to protect the intestinal microbiome in patients.